earnings
confidence high
sentiment positive
materiality 0.70
Vivos Therapeutics Q3 revenue up 17% to $3.9M; operating loss down 27%; FDA clearance for pediatric OSA
Vivos Therapeutics, Inc.
2024-Q3 EPS reported
-$1.94
revenue$11,333,000
- Q3 2024 revenue $3.9M (+17% YoY); gross margin improved to 60% from 53%.
- Operating loss decreased $1M (27%) YoY; operating expenses down 8% — ninth consecutive quarter of reduction.
- Cash and equivalents $6.3M, stockholders' equity $7.7M; raised $4.3M via registered direct equity offering in Sept.
- First FDA 510(k) clearance for treating moderate-to-severe OSA in children 6-17; AMA CPT codes for Vivos devices effective Jan 1, 2025.
- Over 47,000 patients treated globally; new marketing model expanding to two more Colorado locations by early 2025.